Rate Video

ASCO 2020 | Axitinib plus pembrolizumab in advanced RCC

Michael Atkins • 26 May 2020

Genitourinary Cancer Kidney Cancer Axitinib Pembrolizumab

Immuno-Oncology

Michael Atkins, MD, of Georgetown University, Washington, DC, reports long-term efficacy and safety from a phase Ib study investigating the combination of axitinib and pembrolizumab in advanced renal cell carcinoma patients. This video was recorded via an online conference call with the Video Journal of Oncology (VJOncology).

Looking to the future of RCC treatment

Can the efficacy of one drug be influenced by another?

Michael Atkins • 8 Sep 2017

Pembrolizumab monotherapy and pembro-axitinib for RCC

What's the best option in the treatment of melanoma?

Michael Atkins • 8 Sep 2017

Related Videos

PSMA dRT: PSMA PET/CT before radiotherapy in prostate cancer

Jeremie Calais • 22 Apr 2021

Clinical utility of liquid biopsies in prostate cancer

Arpit Rao • 19 Apr 2021

Upcoming advances in prostate cancer: PARPi, CDK4/6, lutetium PSMA therapy & CAR-T approaches

Arpit Rao • 19 Apr 2021

RAMP: Phase Ib study of rucaparib & enzalutamide in mCRPC

Arpit Rao • 19 Apr 2021